Table 6.
Evaluation response of Tn/Tm of aNSCLCs received immunotherapy.
| Cells | Groups | n | Disease control | Progressive Disease | |
|---|---|---|---|---|---|
| 92 | PR = 19 | SD = 34 | PD = 39 | ||
| n (%) | n (%) | n (%) | |||
| CD4+ Tn % | ≥ 1.8% | 71 | 18 (25%) | 31 (44%) | 22 (31%) |
| < 1.8% | 21 | 1 (5%) | 3 (14%) | 17 (81%) | |
| CD4+ Tn | ≥ 5.5 cells/μL | 66 | 19 (29%) | 28 (42%) | 19 (29%) |
| < 5.5 cells/μL | 26 | 0 | 6 (23%) | 20 (77%) | |
| CD4+ Tscm % | ≥ 17% | 48 | 10 (21%) | 19 (39.5%) | 19 (39.5%) |
| < 17% | 44 | 9 (20%) | 15 (34%) | 20 (46%) | |
| CD4+ Tscm | ≥ 64.5 cells/μL | 46 | 14 (30%) | 21 (46%) | 11 (24%) |
| < 64.5 cells/μL | 46 | 5 (11%) | 13 (28%) | 28 (61%) | |
| CD4+ Tcm % | ≥ 29.85% | 46 | 12 (26%) | 19 (41%) | 15 (33%) |
| < 29.85% | 46 | 7 (15%) | 15 (33%) | 24 (52%) | |
| CD4+ Tcm | ≥ 116.5 cells/μL | 46 | 14 (30%) | 21 (46%) | 11 (24%) |
| < 116.5 cells/μL | 46 | 5 (11%) | 13 (28%) | 28 (61%) | |
| CD4+ Tem % | ≥ 22.1% | 47 | 11 (23%) | 19 (41%) | 17 (36%) |
| < 22.1% | 45 | 8 (18%) | 15 (33%) | 22 (49%) | |
| CD4+ Tem | ≥ 80 cells/μL | 46 | 14 (30%) | 21 (46%) | 11 (24%) |
| < 80 cells/μL | 46 | 5 (11%) | 13 (28%) | 28 (61%) | |
| CD4+ Tte % | ≥ 0.35% | 56 | 11 (20%) | 21 (38%) | 24 (42%) |
| < 0.35% | 36 | 8 (22%) | 13 (36%) | 15 (42%) | |
| CD4+ Tte | ≥ 2 cells/μL | 50 | 11 (22%) | 19 (38%) | 20 (40%) |
| < 2 cells/μL | 42 | 8 (19%) | 15 (36%) | 19 (45%) | |
| CD8+ Tn % | ≥ 1.35% | 30 | 5 (17%) | 16 (53%) | 9 (30%) |
| < 1.35% | 62 | 14 (23%) | 18 (29%) | 30 (48%) | |
| CD8+ Tn | ≥ 2 cells/μL | 59 | 11 (19%) | 30 (51%) | 18 (30%) |
| < 2 cells/μL | 33 | 8 (24%) | 4 (12%) | 21 (64%) | |
| CD8+ Tscm % | ≥ 9.55% | 44 | 8 (18%) | 19 (43%) | 17 (39%) |
| < 9.55% | 48 | 11 (23%) | 15 (31%) | 22 (46%) | |
| CD8+ Tscm | ≥ 23.5 cells/μL | 43 | 11 (26%) | 23 (53%) | 9 (21%) |
| < 23.5 cells/μL | 49 | 8 (16%) | 11 (23%) | 30 (61%) | |
| CD8+ Tcm % | ≥ 9% | 47 | 10 (21%) | 18 (38%) | 19 (41%) |
| < 9% | 45 | 9 (20%) | 16 (36%) | 20 (44%) | |
| CD8+ Tcm | ≥ 25.5 cells/μL | 46 | 12 (26%) | 19 (41%) | 15 (33%) |
| < 25.5 cells/μL | 46 | 7 (15%) | 15 (33%) | 24 (52%) | |
| CD8+ Tem % | ≥ 21.3% | 46 | 10 (22%) | 15 (33%) | 21 (45%) |
| < 21.3% | 46 | 9 (20%) | 19 (41%) | 18 (39%) | |
| CD8+ Tem | ≥ 57 cells/μL | 47 | 12 (26%) | 17 (36%) | 18 (38%) |
| < 57 cells/μL | 45 | 7 (15%) | 17 (38%) | 21 (47%) | |
| CD8+ Tte % | ≥ 6.55% | 46 | 9 (20%) | 20 (44%) | 17 (36%) |
| < 6.55% | 46 | 10 (22%) | 14 (30%) | 22 (48%) | |
| CD8+ Tte | ≥ 15 cells/μL | 48 | 11 (23%) | 23 (48%) | 14 (29%) |
| < 15 cells/μL | 44 | 8 (18%) | 11 (25%) | 25 (57%) | |